

13-ICML POSTER SESSION - Marquee Parco Ciani - from Wednesday, June 17th h 12:00 to Friday, June 19th 18:30 - authors in front of posters on Thursday and Friday from 12:30 to 13:00

Abstract nr.	First Author	TITLE	TOPIC
148	Dr Blaker, Yngvild	The impact of the microenvironment on transformation and prognosis of non-Hodgkin lymphoma in the Rituximab era	PATHOLOGY AND BIOLOGY
149	Dr Yang, Zhi-Zhang	Co-expression of PD-1, TIM-3 and LAG-3 defines exhaustion of intratumoral CD8+ T cells in B-cell non-Hodgkin lymphoma	PATHOLOGY AND BIOLOGY
150	Dr Huse, Kanutte	Characterization of inhibitory receptors on tumor-infiltrating T cells in follicular lymphoma to reveal novel targets for immunotherapy	PATHOLOGY AND BIOLOGY
151	Dr Magnano, Laura	T-cell subpopulations quantified by flow cytometry in lymph node cell suspensions identify a group of patients with follicular lymphoma with favorable outcome	PATHOLOGY AND BIOLOGY
152	Mr Sewastianik, Tomasz	TXN overexpression in diffuse large B-cell lymphoma cells attenuates oxidative stress-induced proapoptotic activity of FOXO1 transcription factor	PATHOLOGY AND BIOLOGY
153	Dr Jablonska, Ewa	MiR-155 amplifies BCR signaling by targeting its multiple negative regulators in DLBCL	PATHOLOGY AND BIOLOGY
154	Dr Deutsch, Alexander	NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy	PATHOLOGY AND BIOLOGY
155	Dr Pan-Hammarström, Qiang	Exome and whole genome sequencing reveals novel genetic alterations in diffuse large B cell lymphomas derived from Chinese patients	PATHOLOGY AND BIOLOGY
156	Ms Burkhard, Regula	Identification of candidate predisposition genes in a family with two female siblings affected by mediastinal diffuse large B-cell lymphoma	PATHOLOGY AND BIOLOGY
157	Dr Chiappella, Annalisa	Prognostic impact of cell of origin profile in young patients with high risk diffuse large B cell lymphoma: results of the BIO-DLCL04 trial of Fondazione Italiana Linfomi	PATHOLOGY AND BIOLOGY
158	Dr Farooq, Umar	Cell of origin is not associated with survival after DLBCL relapse	PATHOLOGY AND BIOLOGY
159	Dr Valera, Alexandra	Impact on survival of MYC genetic alterations but not MYD88L265P mutation in primary testicular DLBCL	PATHOLOGY AND BIOLOGY
160	Dr Rovira, Jordina	MYD88 L265P mutations, but not other variants, identify a subgroup of patients with ABC diffuse large B-cell lymphoma, extranodal involvement and poor outcome	PATHOLOGY AND BIOLOGY
161	Dr Lu, Ting-Xun	MYC or BCL2 copy number aberrations is a strong predictor of outcome in patients with diffuse large B-cell lymphoma	PATHOLOGY AND BIOLOGY
162	Dr Landsburg, Daniel	Analysis of "double-hit" lymphoma cases by genetic subtype	PATHOLOGY AND BIOLOGY
163	Dr Juskevicius, Darius	Distinct patterns of genetic evolution of relapsing diffuse large B-cell lymphoma revealed by genome copy number aberration analysis	PATHOLOGY AND BIOLOGY
164	Dr Broséus, Julien	Relapsed DLBCLs present frequent copy number variations of genes involved in lymphomagenesis with different pattern between early- and late-relapsed DLBCLs	PATHOLOGY AND BIOLOGY
165	Dr Pan-Hammarström, Qiang	Genetic heterogeneity and clonal evolution in primary and relapsed mantle cell lymphomas	PATHOLOGY AND BIOLOGY
166	Dr Kumar, Anita	Prognostic Significance of Genomic Alterations in Mantle Cell Lymphoma	PATHOLOGY AND BIOLOGY
167	Dr Samaniego, Felipe	FGF SIGNALING SUPPORTS MANTLE CELL LYMPHOMA SURVIVAL IN THE PRESENCE OF MESENCHYMAL STROMAL CELLS	PATHOLOGY AND BIOLOGY
168	Dr Tessoulin, Benoît	PRIMA-1Met induces myeloma and mantle cell lymphoma cell death, by impairing ROS/GSH balance.	PATHOLOGY AND BIOLOGY
169	Dr Crompot, Emerence	Chronic Lymphocytic Leukemia B-cells are rescued from apoptosis by extracellular vesicles from bone marrow mesenchymal stromal cells	PATHOLOGY AND BIOLOGY
170	Mr Van Damme, Michaël	Prognostic significance of TET and IDH mRNA expression in chronic lymphocytic leukemia	PATHOLOGY AND BIOLOGY
171	Dr Reddy, Jay	Optimal Treatment Strategies for Early-Stage Hodgkin's Lymphoma with B Symptoms and Bulky Disease at Presentation	HODGKIN LYMPHOMA
172	Dr Rossi, Cédric	Infradiaphragmatic Hodgkin Lymphoma: long term outcome improved by radiotherapy-chemotherapy VS chemotherapy alone.	HODGKIN LYMPHOMA
173	Dr O'Rourke, Noelle	Consolidation radiation after ABVD is effective treatment for selected patients with Hodgkin's lymphoma (HL) with interim PET positive scans.	HODGKIN LYMPHOMA
174	Dr Dedeckova, Katerina	Pencil Beam Scanning Proton Therapy for Lymphoma Patients with Mediastinal Involvement: A Dosimetric Study and Preliminary Clinical Data	HODGKIN LYMPHOMA
175	Dr Cutter, David	Cardiac Radiation Dose and Predicted Cardiac Mortality in the UK NCRI RAPID Trial in early stage Hodgkin Lymphoma	HODGKIN LYMPHOMA
176	Dr Hapgood, Greg	Risk of relapse in classical Hodgkin lymphoma at event-free time points and survival comparison to the general population in British Columbia.	HODGKIN LYMPHOMA
177	Dr Bonthapally, Vijay	Healthcare utilization in the AETHERA trial: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post ASCT	HODGKIN LYMPHOMA
178	Dr Broccoli, Alessandro	Safety and efficacy of bendamustine after the failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: experience on 27 patients.	HODGKIN LYMPHOMA
179	Dr Rosenberg, Aaron	Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder (HL-PTLD): A Comparative Analysis of Prognosis and Survival	HODGKIN LYMPHOMA
180	Dr Spina, Francesco	THE RELAPSE TIME AFTER AUTOLOGOUS TRANSPLANT OR REFRACTORINESS DO NOT IMPACT THE SURVIVAL OF HODGKIN'S LYMPHOMA TREATED WITH ALLOGENEIC TRANSPLANT	HODGKIN LYMPHOMA
181	Dr Ying, Zhitao	First in-patient proof of safety and efficacy of a 4th generation chimeric antigen receptor-modified T cells for the treatment of R/R CD30-positive lymphoma	HODGKIN LYMPHOMA

182	Dr Patmore, Russell	Chronic lymphocytic leukaemia treatment and outcome in the UK's population-based Haematological Malignancy Research Network	CLL
183	Dr Gagez, Anne-Laure	Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B-CLL cells and FCGR3A polymorphism. A study of FCGCLL/MW and GOELAMS groups.	CLL
184	Dr Lepretre, Stephane	Results of a Phase II randomizing intensified rituximab pre-phase followed by standard FCR vs standard FCR in previously untreated patients with Active B-CLL.	CLL
185	Dr Mulligan, Stephen	A Randomised Study of F(C)R in Fit, Elderly Patients with Chronic Lymphocytic Leukaemia (CLL) shows high response rates and a dose intensity effect	CLL
186	Dr Tiacci, Enrico	Targeting Mutated BRAF with Vemurafenib is Safe and Highly Active in Relapsed/Refractory Hairy Cell Leukemia: a Phase-2 Italian Clinical Trial (HCL-PG01)	CLL
187	Dr El-Najjar, Inas	The clinical course of patients with follicular lymphoma in the rituximab era	INDOLENT LYMPHOMA
188	Dr Bachy, Emmanuel	Event-free Survival at 12 Months and Subsequent Overall Survival in Patients with Follicular Lymphoma Managed in the Rituximab Era	INDOLENT LYMPHOMA
189	Dr Mendez, Miriam	Follicular lymphoma and clinical characteristics of histologic transformation	INDOLENT LYMPHOMA
190	Dr Alonso-Álvarez, Sara	RISK INCIDENCE OF FOLLICULAR LYMPHOMA TRANSFORMATION: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE SPANISH GELTAMO GROUP	INDOLENT LYMPHOMA
191	Dr Cheah, Chan Yoon	Comparison of lenalidomide and rituximab with chemoimmunotherapy in patients with untreated grade 1-2 follicular lymphoma treated at the MD Anderson Cancer Center	INDOLENT LYMPHOMA
192	Dr Fowler, Nathan	Extended Dosing Lenalidomide with Intensified Rituximab in Untreated Indolent NHL	INDOLENT LYMPHOMA
193	Dr Salles, Gilles	Idelalisib in Follicular Lymphoma (FL): Efficacy and Safety From a Phase 2 Study	INDOLENT LYMPHOMA
194	Dr Coutre, Steven	Idelalisib monotherapy results in durable responses in patients with relapsed or refractory Waldenströms macroglobulinemia (WM)	INDOLENT LYMPHOMA
195	Dr Fornecker, Luc-Matthieu	Clinical outcome in the PRIMA study for young patients with follicular lymphoma after first-line immunochemotherapy.	INDOLENT LYMPHOMA
196	Dr Vidal Fisher, Liat	Rituximab Maintenance (MR) improves PFS and OS in all Patients (pts) with Follicular Lymphoma (FL) - Individual Patient Data (IPD) meta-analysis	INDOLENT LYMPHOMA
197	Dr Davies, Andrew	Comparison of subcutaneous and intravenous rituximab in the maintenance setting: Updated safety results of the phase III SABRINA study in patients with follicular lymphoma	INDOLENT LYMPHOMA
198	Dr Stathis, Anastasios	Phase II study for the evaluation of feasibility, activity and safety of Bendamustine and Ofatumumab in combination in marginal zone B-cell lymphomas (MZL)	INDOLENT LYMPHOMA
199	Dr Castillo, Jorge	Higher risk of rituximab intolerance in patients with Waldenström Macroglobulinemia	INDOLENT LYMPHOMA
200	Dr Castillo, Jorge	Histological transformation in patients with Waldenström macroglobulinemia	INDOLENT LYMPHOMA
201	Dr Uldrick, Thomas	Outcomes in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease patients treated with rituximab and liposomal doxorubicin (R-Dox)	INDOLENT LYMPHOMA
202	Dr Verhoef, Gregor	Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma (MCL) receiving VR-CAP vs R-CHOP in the phase 3 LYM-3002 study	MANTLE CELL LYMPHOMA
203	Dr Klener, Pavel	R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma not Eligible for High-Dose Therapy: preliminary results at 2 years follow-up.	MANTLE CELL LYMPHOMA
204	Dr Zelenetz, Andrew	Clinical, metabolic and molecular responses with sequential R-CHOP, high-dose cytarabine, and iodine-131 tositumomab-based transplant in Mantle Cell Lymphoma	MANTLE CELL LYMPHOMA
205	Dr Ruan, Jia	Multi-center phase II study with lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: survival update and health-related quality-of-life analysis	MANTLE CELL LYMPHOMA
206	Dr Trněný, Marek	Subgroup Analysis of the Phase II Randomized MCL-002 (SPRINT) Study of Lenalidomide vs Investigator's Choice in Relapsed/Refractory Mantle Cell Lymphoma	MANTLE CELL LYMPHOMA
207	Dr Martin, Peter	Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma	MANTLE CELL LYMPHOMA
208	Dr Lee, Hun	Atrial Fibrillation in Ibrutinib Treated Relapsed Mantle Cell Lymphoma, Clinical and Laboratory analysis of risk factors	MANTLE CELL LYMPHOMA
209	Dr Cortelazzo, Sergio	High Dose Sequential Chemotherapy with Rituximab and ASCT as First Line Therapy in Adult MCL Patients: Clinical and Molecular Response of the MCL0208 Trial, a FIL Study.	MANTLE CELL LYMPHOMA
210	Dr Villa, Diego	The standard, revised and a simplified International Prognostic Index reliably predict outcome in patients with PET/CT-staged DLBCL treated with R-CHOP	AGGRESSIVE B-CELL LYMPHOMA
211	Dr El-Galaly, Tarec	Female patients with DLBCL and involvement of the reproductive organs have poor outcomes and markedly increased risk of CNS relapse with R-CHOP(-like) therapy	AGGRESSIVE B-CELL LYMPHOMA
212	Dr Kansara, Roopesh	Evaluation of the site of central nervous system (CNS) relapse in patients with Diffuse Large B-cell lymphoma (DLBCL) by the CNS risk model	AGGRESSIVE B-CELL LYMPHOMA

213	Dr Modvig, Lena	Clinical and Treatment-Related Features Determining the Risk of Late Relapse in Patients with Diffuse Large B-cell Lymphoma	AGGRESSIVE B-CELL LYMPHOMA
214	Dr Nastoupil, Loretta	Diffuse Large B-cell Lymphoma Survival by Subtype: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry algorithms	AGGRESSIVE B-CELL LYMPHOMA
215	Dr Casasnovas, Olivier	Spleen involvement identified on baseline PET imaging influences outcome of young patients with high risk diffuse large B cell lymphoma treated with R-CHOP14 but not R-ACVBP	AGGRESSIVE B-CELL LYMPHOMA
216	Dr Moccia, Alden	Excellent outcome of patients over 80 years with diffuse large B-cell lymphoma (DLBCL) treated with standard therapy: A large retrospective study from 4 Institutions.	AGGRESSIVE B-CELL LYMPHOMA
217	Dr Afifi, Salma	Vincristine omission, but not dose reduction, is associated with decreased survival in elderly DLBCL patients	AGGRESSIVE B-CELL LYMPHOMA
218	Dr Conconi, Annarita	Outcome analysis of diffuse large B cell lymphoma (DLBCL) in HIV-infected and immunocompetent (IC) patients: The Swiss HIV Cohort study (SHCS)	AGGRESSIVE B-CELL LYMPHOMA
219	Dr Korfel, Agnieszka	Secondary CNS lymphoma in the rituximab-era: Data on the first 100 patients from a prospective registry	AGGRESSIVE B-CELL LYMPHOMA
220	Dr Leppä, Sirpa	Dose-Dense Chemoimmunotherapy and Early CNS Prophylaxis for High-Risk DLBCL. –Interim Results from a Nordic Phase II Study	AGGRESSIVE B-CELL LYMPHOMA
221	Dr Gilbertson, Michael	Systemic high-dose methotrexate (HD-MTX) consolidation in poor-risk diffuse large B-cell lymphoma is associated with improved survival in Germinal Centre B-cell phenotype	AGGRESSIVE B-CELL LYMPHOMA
222	Dr McMillan, Andrew	The addition of Rituximab to CODOX-M & IVAC in first Line therapy of poor risk Burkitt Lymphoma (IPI 3-5) yields an excellent outcome: a Phase 2 UK NCRI/LLR Trial (LLR 04058)	AGGRESSIVE B-CELL LYMPHOMA
223	Dr Ternant, David	A pharmacokinetic-pharmacodynamic model allowing to optimize rituximab dosing regimen according to baseline tumor burden in DLBCL patients. A LYSA group study.	AGGRESSIVE B-CELL LYMPHOMA
224	Dr Zaja, Francesco	Panobinostat for Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma: a Phase II Study of the Fondazione Italiana Linfomi (FIL)	AGGRESSIVE B-CELL LYMPHOMA
225	Dr Kreher, Stephan	Prognostic impact of immunohistological profiling in primary CNS lymphoma	EXTRANODAL LYMPHOMA
226	Prof Gyan, Emmanuel	Addition of Rituximab to the Treatment of Newly Diagnosed Primary CNS Lymphoma is Associated with Improved Outcome: A French LOC Network study	EXTRANODAL LYMPHOMA
227	Dr Lopez-Parra, Miriam	BAM induction followed by autologous stem cell transplantation for patients with primary central nervous system lymphoma: a multicenter study from the Spanish group GEL-TAMO	EXTRANODAL LYMPHOMA
228	Dr Choquet, Sylvain	High efficiency and tolerance of Temozolomide in relapse/refractory primary vitreo-retineal lymphoma: a multicentric study from the LOC network	EXTRANODAL LYMPHOMA
229	Dr Korfel, Agnieszka	Temsirolimus for primary CNS lymphoma	EXTRANODAL LYMPHOMA
230	Dr Teckie, Sewit	Long-Term Outcome of 490 Patients with Early-Stage Extra-nodal Marginal Zone Lymphoma	EXTRANODAL LYMPHOMA
231	Dr Bellei, Monica	Clinical Characteristics and Patterns of Care of Patients (pts) with Peripheral T-cell Lymphoma (PTCLs) according to age at time of diagnosis: A T-Cell Project snapshot.	T-CELL LYMPHOMA
232	Dr Nabhan, Chadi	Characteristics and Patterns of Care of Patients (pts) ≥70 years with T-cell non-Hodgkin Lymphoma (TCL) in the United States (US)	T-CELL LYMPHOMA
233	Dr Julamane, Jakrawadee	A large prospective multicenter study of peripheral T-cell lymphoma in Thailand: clinical, histopathology, treatment outcomes, and survival	T-CELL LYMPHOMA
234	Dr Lin, Tongyu	A proposal of a new staging system for extranodal natural killer T-cell lymphoma, nasal-type.	T-CELL LYMPHOMA
235	Dr Kurita, Daisuke	A clinicopathological study of Lennert lymphoma and possible prognostic factors	T-CELL LYMPHOMA
236	Dr Bunworasate, Udomsak	SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA IN THAILAND: CLINICAL OUTCOMES, TREATMENTS, AND PROGNOSTIC FACTORS	T-CELL LYMPHOMA
237	Dr Zambello, Renato	Immunophenotypic heterogeneity of T-LGLL: clinical and biological implications	T-CELL LYMPHOMA
238	Dr Laurent, Camille	Breast Implant Associated Anaplastic Large cell Lymphoma: a new distinct clinicopathologic entity.	T-CELL LYMPHOMA
239	Dr Feldman, Andrew	Molecular Heterogeneity of ALK-negative Anaplastic Large Cell Lymphoma	T-CELL LYMPHOMA
240	Dr Vergé, Véronique	NPM- ALK antibody titer in ALK positive Anaplastic Large Cell Lymphoma (ALCL) : long term follow-up, the French pediatric experience.	T-CELL LYMPHOMA
241	Dr Damm-Welk, Christine	ALK binding sites of anti-ALK-antibodies from patients with anaplastic large cell lymphoma analyzed by peptide array	T-CELL LYMPHOMA
242	Dr Lee, Bo-Hee	Clinical impact of induction treatment and optimal timing of radiotherapy for the limited-stage NK/T-cell lymphoma	T-CELL LYMPHOMA

243	Prof Song, Yuqin	Polyethylene glycol conjugated asparaginase-CHOP in adult newly diagnosed extranodal NK/T-cell lymphoma: a multi-center prospective phase II study	T-CELL LYMPHOMA
244	Dr Qi, Shunan	Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population	T-CELL LYMPHOMA
245	Dr Hui-Qiang, Huang	Clinical Outcome of P-Gemox for Newly Diagnosed Stage III/IV or Relapsed/Refractory ENKTL	T-CELL LYMPHOMA
246	Dr Pellegrini, Cinzia	Interim results of a phase II study of the Fondazione Italiana Linfomi (FIL) on gemcitabine plus romidepsin (GEMRO) in relapsed/refractory peripheral T cell lymphoma patients	T-CELL LYMPHOMA
247	Dr Horwitz, Steven	The role of transplant in the treatment of Peripheral T-cell Lymphomas (PTCLs): an analysis from the T-Cell project database.	T-CELL LYMPHOMA
248	Dr Suzuki, Ritsuro	Phase II study of SMILE chemotherapy for relapsed/refractory peripheral T-cell lymphoma	T-CELL LYMPHOMA
249	Dr Reboursiere, Emilie	Bendamustine treatment in refractory/relapsed T cell lymphomas: a retrospective multicenter study	T-CELL LYMPHOMA
250	Dr Witzig, Thomas	The mTORC1 Inhibitor Everolimus Produces Tumor Responses in Patients with Relapsed T-cell Non-Hodgkin Lymphoma	T-CELL LYMPHOMA
251	Dr Cove-Smith, Laura	Novel Cardiac MRI and Circulating Biomarkers Model of Anthracycline-induced Cardiotoxicity suggests that "Healthier Hearts" may be at Greatest Risk	IMAGING
252	Dr Casasnovas, Olivier	Baseline metabolic tumor burden in DLBCL affects response to immuno-chemotherapy and patients outcome through influence of rituximab pharmacokinetics. A LYSA group study.	IMAGING
253	Dr Dann, Eldad	Comparison of dynamic visual score and Deauville score accuracy of interim PET/CT in 339 patients with Hodgkin lymphoma treated on the Israeli H2 protocol	IMAGING
254	Dr Puccini, Benedetta	Role of bone marrow biopsy (BMB) in classic Hodgkin Lymphoma (cHL) staging in FDG-PET/CT era.	IMAGING
255	Dr Abou Yehia, Zeinab	Hodgkin Lymphoma: PET-CT or bone marrow biopsy?	IMAGING
256	Dr Perry, Chava	The role of PET-CT in assessment of bone marrow involvement in patients with follicular lymphoma	IMAGING
257	Dr Faes, Caroline	PROGNOSTIC VALUE OF INTERIM FDG-PET/CT IN 100 DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP ACCORDING TO INTERPRETATION CRITERIA AND PRETHERAPEUTIC PROGNOSTIC FACTORS	IMAGING
258	Dr Mikhaeel, N.George	Blinded evaluation of the prognostic value of FDG-PET/CT after 2 cycles of RCHOP in DLBCL – UK-NCRI study	IMAGING
259	Dr El-Galaly, Tarec	No survival benefit associated with routine imaging for classical Hodgkin lymphoma in complete remission: A Danish-Swedish population-based study	IMAGING
260	Dr Kase, Julia	A cross-species pan-omics approach in a transgenic mouse lymphoma model to decipher treatment failure in diffuse large B-cell lymphomas	PRE-CLINICAL STUDIES
261	Dr Chiron, David	Biological Rational for Sequential Targeting of Bruton Tyrosine Kinase and Bcl2 to Overcome Cd40-induced BH3-mimetics Resistance in Mantle Cell Lymphoma	PRE-CLINICAL STUDIES
262	Dr Szydowski, Maciej	Inhibition of PIM kinases decreases protein translation and attenuates Myc and NFkB activity in Diffuse Large B-cell Lymphoma cell lines.	PRE-CLINICAL STUDIES
263	Dr Bialopiotrowicz, Emilia	PIM kinases promote chronic lymphocytic leukemia cells survival through a pleiotropic mechanism involving modulation of CXCR4-triggered mTOR pathway	PRE-CLINICAL STUDIES
264	Dr Roue, Gael	Preclinical evaluation of the novel pleiotropic BCR kinase inhibitor IQS019 in in vitro and in vivo models of B lymphoid neoplasms	PRE-CLINICAL STUDIES
265	Mr Kiliszek, Przemysław	SYK inhibition triggers DLBCL cell death via a mechanism linking FOXO1 activation, DREAM cleavage and expression of a proapoptotic BCL2 family member, HRK.	PRE-CLINICAL STUDIES
266	Dr Coyle, Michael	Transcriptomic profiling of response to PI3K inhibition by BKM120 in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL)	PRE-CLINICAL STUDIES
267	Dr Lim, Soon Thye	Expression of PI3K isoforms and PTEN in follicular lymphoma and diffuse large B-cell lymphoma	PRE-CLINICAL STUDIES
268	Dr Paul, Juliane	Copanlisib attenuates both BCR-dependent and BCR-independent activation of NFkB in DLBCL cells	PRE-CLINICAL STUDIES
269	Dr Chung, Elaine	Pre-clinical lymphoma models show high sensitivity to the small molecule YK-4-279	PRE-CLINICAL STUDIES
270	Dr Dlouhy, Ivan	IRAK1/4 and BET bromodomain inhibitions converge in NF-κB blockade and offer synergistic antitumoral activity in ABC-DLBCL with MYD88 mutation	PRE-CLINICAL STUDIES
271	Dr Mensah, Afua	The BET bromodomain inhibitor OTX015 (MK-8628) affects the expression of microRNAs involved in the pathogenesis of lymphoma: in vitro and in vivo evidence	PRE-CLINICAL STUDIES
272	Dr Tarantelli, Chiara	OTX015 (MK-8628) targets genes with high levels of promoter H3K4me3 involved in key signalling pathways in splenic marginal zone lymphoma and mantle cell lymphoma	PRE-CLINICAL STUDIES
273	Dr Tarantelli, Chiara	Pixantrone has pre-clinical synergistic activity when combined with targeted agents in diffuse large B-cell lymphoma.	PRE-CLINICAL STUDIES
274	Dr Romanelli, Angela	Novel CD37-Targeting Antibody-Drug Conjugate (ADC), IMG529, Has Synergistic Activity in Combination with Rituximab in Non-Hodgkin Lymphoma (NHL) Models	PRE-CLINICAL STUDIES
275	Dr Klein, Christian	A variant of obinutuzumab with abolished ADCC, ADCP and CDC is as efficient as rituximab in B cell depletion and antitumor activity	PRE-CLINICAL STUDIES
276	Dr Marie-Cardine, Anne	The Yin-Yang of KIR3DL2 in CTCL malignant T cells	PRE-CLINICAL STUDIES
277	Dr Jain, Salvia	Targeting the MUC1-C oncoprotein is associated with downregulation of TIGAR and ROS-mediated cutaneous T-cell lymphoma cell death	PRE-CLINICAL STUDIES
278	Dr Evens, Andrew	MYC and CHK1 Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models With Anti-Proteasomal Therapy	PRE-CLINICAL STUDIES

279	Dr Zullo, Kelly	Alisertib Exhibits Broad Activity And Selectively Synergizes With Romidepsin In Preclinical Models Of T-Cell Lymphoma	PRE-CLINICAL STUDIES
280	Dr Kater, Arnon	Interim Analysis of a Phase 1b Study Evaluating the Safety of GS-9820, a Second-Generation PI3K δ -inhibitor, in Relapsed/Refractory Lymphoid Malignancies	EARLY CLINICAL STUDIES
281	Dr Douglas, Mark	Duvelisib, an oral dual inhibitor of PI3K- δ , γ , modulates serum chemokines and cytokines in patients with relapsed/refractory B and T cell lymphoma	EARLY CLINICAL STUDIES
282	Dr Johnston, Patrick	Everolimus plus R-CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 [Alliance])	EARLY CLINICAL STUDIES
283	Dr Witzens-Harig, Mathias	Safety and clinical activity of Temsirolimus in combination with Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma	EARLY CLINICAL STUDIES
284	Dr Lunning, Matthew	Ublituximab + TGR-1202 demonstrates activity and favorable safety profile in relapsed/refractory B-cell NHL and high-risk CLL	EARLY CLINICAL STUDIES
285	Dr Viardot, Andreas	Blinatumomab Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in An Open-Label, Phase 2 Study: Safety, Efficacy, and Late Responses	EARLY CLINICAL STUDIES
286	Dr Kroschinsky, Frank	Phase I dose-escalation study of BI 836826 in patients (pts) with relapsed or refractory non-Hodgkin lymphoma (NHL) of B cell origin	EARLY CLINICAL STUDIES
287	Dr Kolstad, Arne	Results of a phase I study of 177Lu-DOTA-HH1 antibody radionuclide conjugate for patients with relapsed CD37+ non-Hodgkins lymphomas	EARLY CLINICAL STUDIES
OT07	Dr Dreyling, Martin	CHRONOS-1: Phase II trial of intravenous phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib in patients with relapsed/refractory indolent NHL	ONGOING TRIALS
OT08	Dr Brenner, Louis	Design of a Phase 1/2, open-label, dose-escalation trial of the Toll-like receptor antagonist IMO-8400 in patients with MYD88 L265P-positive diffuse large B-cell lymphoma	ONGOING TRIALS
OT09	Dr Wang, Michael	Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial	ONGOING TRIALS
OT10	Dr Leonard, John	Efficacy and safety of lenalidomide and rituximab vs placebo and rituximab in a phase 3 trial in relapsed/refractory non-Hodgkin lymphoma	ONGOING TRIALS
OT11	Dr Chiappella, Annalisa	FIL-VERAL12: phase II randomized study with Rituximab-DHAP +/- Bortezomib as induction in young relapsed/refractory Diffuse Large B-cell Lymphoma eligible to transplant.	ONGOING TRIALS
OT12	Dr Cox, M Christina	A phase I trial to evaluate the safety and activity of a-Dendritic Cell-based immunotherapy in indolent non-Hodgkin lymphomas (IFN-DC-2 Study)	ONGOING TRIALS
OT13	Dr Merli, Francesco	The "Elderly Project" by the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma.	ONGOING TRIALS
OT14	Dr Kutsch, Nadine	CLLR3 A randomized Phase II trial evaluating the chemotherapies FC/ B combined with GA101 followed by GA101 maintenance in relapsed/ refractory CLL	ONGOING TRIALS
OT15	Dr Freeman, Ciara	Phase Ib study exploring IL-6 receptor blockade to prevent infusion-related reactions in patients with previously untreated CLL receiving obinutuzumab plus chlorambucil	ONGOING TRIALS